Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CLBR-001 in Hormone receptor positive breast cancer: NCT06878248 Clinical Landscape Report 2026
15 October 2026
NCT06878248 clinical landscape for Hormone receptor positive breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Pembrolizumab in Triple Negative Breast Cancer: NCT06880029 Clinical Landscape Report 2026
15 October 2026
NCT06880029 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Deucravacitinib in Lupus Erythematosus, Cutaneous: NCT06875960 Clinical Landscape Report 2026
15 October 2026
NCT06875960 clinical landscape for Lupus Erythematosus, Cutaneous: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zoledronic Acid in Triple Negative Breast Cancer: NCT06876636 Clinical Landscape Report 2026
15 October 2026
NCT06876636 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Advanced Triple-Negative Breast Carcinoma: NCT06878625 Clinical Landscape Report 2026
15 October 2026
NCT06878625 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Adebrelimab in Muscle Invasive Bladder Carcinoma: NCT06879145 Clinical Landscape Report 2026
15 October 2026
NCT06879145 clinical landscape for Muscle Invasive Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Fludarabine Phosphate in High grade B-cell lymphoma: NCT06879340 Clinical Landscape Report 2026
15 October 2026
NCT06879340 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vunakizumab in Systemic Lupus Erythematosus: NCT06881290 Clinical Landscape Report 2026
15 October 2026
NCT06881290 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LXP-1788 in Refractory Malignant Solid Neoplasm: NCT06883539 Clinical Landscape Report 2026
15 October 2026
NCT06883539 clinical landscape for Refractory Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Metformin Hydrochloride in Metastatic Renal Cell Carcinoma: NCT06884683 Clinical Landscape Report 2026
15 October 2026
NCT06884683 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ALK.CAR-T cells(University of Turin/Boston Children) in High grade B-cell lymphoma: CTRI/2025/03/082608 Clinical Landscape Report 2026
15 October 2026
CTRI/2025/03/082608 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Montelukast sodium in Sarcoma: NCT06887673 Clinical Landscape Report 2026
15 October 2026
NCT06887673 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.